Selected Techniques for Delivery of Drugs to the Brain (CPB 0731, reviewed 2026-10-21)
Effective date
Not stated in the notice
Identified
Oct 27, 2026
Summary
Aetna Clinical Policy Bulletin 0731 (last review 10/21/2026) states that convection-enhanced delivery of drugs into brain parenchyma and low-intensity MR-guided focused ultrasound mediated disruption of the blood-brain barrier for drug delivery are experimental, investigational, or unproven because their safety and effectiveness have not been established. The policy lists CPT 0947T and several ICD-10 codes, including those for malignant neoplasm of brain, Alzheimer's disease, and epilepsy, as not covered for the indications listed in the bulletin.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.
01REQUIREMENTS: Billing team: Review claims for CPT 0947T and the ICD-10 codes listed in the bulletin (C71.0 - C71.9, C79.31, C79.49, G30.0 - G30.9, G40.001 - G40.909, R56.1, R56.9) against the indications in the policy, because the policy lists them as not covered for the indications listed.
02Billing team: Note that the policy considers convection-enhanced delivery and low-intensity MRgFUS blood-brain barrier disruption for drug delivery experimental, investigational, or unproven, since their safety and effectiveness have not been established.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.